FindTrial
Sign In

cabozantinib-s-malate

DRUG3 trials

Sponsors

Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI), Wuerzburg University Hospital

Conditions

Adenocarcinoma of the ProstateAdrenocortical CarcinomaHormone-resistant Prostate CancerRecurrent MelanomaRecurrent Prostate CancerStage IIIA MelanomaStage IIIB MelanomaStage IIIC Melanoma

Phase 1

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
TerminatedNCT01835184
National Cancer Institute (NCI)Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma +3
Start: 2013-05-31Updated: 2014-09-25

Phase 2

Cabozantinib in Advanced Adrenocortical Carcinoma
NCT03612232
Wuerzburg University HospitalAdrenocortical Carcinoma
Start: 2019-06-04End: 2025-04-30Target: 37Updated: 2024-08-19

Unknown Phase

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
CompletedNCT01812668
Barbara Ann Karmanos Cancer InstituteAdenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer +1
Start: 2013-03-31End: 2019-06-18Updated: 2021-08-05

Related Papers

Objective response and prolonged stable disease in refractory adrenocortical carcinoma treated with cabozantinib: An international case series and protocols of phase II clinical trials.
Journal of Clinical Oncology2019-05-20
SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials
Journal of the Endocrine Society2019-04-011 citations
The dynamics of biomarkers and bone imaging associated with oral cabozantinib therapy in metastatic castrate resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2015-05-20